Core Insights - Nanox Imaging Ltd has entered into a distribution agreement with Althea France to introduce its CE-marked Nanox.ARC system in the French healthcare sector, marking its fourth distribution agreement in Europe [1][2][3] Company Overview - Nanox is focused on advancing medical imaging technology, aiming to drive the transition to preventive healthcare through affordable solutions that leverage AI and proprietary digital X-ray sources [4][5] Partnership Details - Althea France will manage the market introduction, sales, and service of the Nanox.ARC, which is a multi-source digital tomosynthesis system designed to enhance diagnostic capabilities at a lower cost compared to traditional systems [2][3] - The partnership is expected to leverage Althea's established relationships with hospitals and clinics across France, facilitating the introduction of Nanox's imaging platform [3] Market Strategy - France is identified as a strategic market for Nanox, with the partnership expected to expand access to high-quality, affordable imaging services for patients [3] - The collaboration follows previous agreements in Greece, Romania, and the Czech Republic, indicating a growing presence in the European market [1][2]

Core Viewpoint - Nanox Imaging Ltd has announced a registered direct offering of 3,826,530 ordinary shares, expected to generate approximately $15 million in gross proceeds, aimed at strengthening its balance sheet and supporting growth initiatives [1][3]. Group 1: Offering Details - The offering involves the sale of 3,826,530 ordinary shares to a single institutional investor, with gross proceeds anticipated to be around $15 million before expenses [1]. - The closing of the offering is expected on or about November 25, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. Group 3: Company Growth Strategy - The CEO of Nanox stated that the capital raise will enhance the company's balance sheet and accelerate key growth initiatives, including technology advancement, market expansion, and AI infrastructure enhancement [3]. - The company aims to make high-quality medical imaging more accessible globally as it scales deployments and expands capabilities [3]. Group 4: Company Overview - Nanox is focused on transitioning to preventive healthcare through affordable medical imaging technologies, leveraging advanced AI and proprietary digital X-ray sources [6]. - The company's ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all aimed at improving early detection and treatment in healthcare [7].

Core Insights - Nanox Imaging Ltd. reported a net loss of $13.7 million for Q3 2025, slightly higher than the $13.6 million loss in Q3 2024, indicating a marginal increase in losses year-over-year [4] - The company achieved revenue of $3.4 million in Q3 2025, up from $3.0 million in the same period last year, driven by teleradiology services and sales of imaging systems and AI solutions [5] - Nanox is focused on advancing its technologies, expanding its market presence, and enhancing operational efficiency, with significant progress made in these areas during the quarter [3] Financial Performance - The gross loss for Q3 2025 was $2.9 million, with a gross loss margin of 84%, compared to a gross loss of $2.8 million and a margin of 93% in Q3 2024 [6] - Revenue from teleradiology services increased to $3.1 million in Q3 2025 from $2.6 million in Q3 2024, with gross profit from these services rising to $0.8 million, reflecting a gross profit margin of approximately 25% [7] - Revenue from AI solutions decreased to $142 thousand in Q3 2025 from $434 thousand in Q3 2024, with a gross loss of $1.9 million [10] Operational Highlights - The company acquired Vaso Healthcare IT to enhance its AI solutions business and entered multiple global collaborations to accelerate the commercialization of Nanox.ARC and AI solutions [3][8] - Clinical trials have expanded to include Cedars-Sinai in Los Angeles and Olympe Imagerie in Paris, supporting the use of Nanox solutions [8] - Nanox has made strides in the European market, establishing distribution partnerships with EXRAY and Althea France SARL [8] Guidance and Future Outlook - The company anticipates deploying over 100 clinical, demo, and commercial units worldwide by the end of 2025, assuming stable macroeconomic conditions [17] - For the year 2026, Nanox expects revenues to reach $35 million, indicating a positive growth trajectory [19] Liquidity and Capital Resources - As of September 30, 2025, Nanox had total cash and marketable securities of $55.5 million, down from $83.2 million at the end of 2024, with negative cash flow from operations of $30.4 million during the reported period [20] - The company had approximately 65.4 million shares outstanding as of September 30, 2025, an increase from 63.8 million shares at the end of 2024 [22]

Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration with Olympe Imagerie, a Paris-based group of independent radiologists, to deploy the Nanox.ARC and expand its clinical research evidence generation program in France. The Nanox.ARC system ...

Core Insights - Nanox Imaging Ltd will report its financial results for Q3 2025 on November 20, 2025, before market open [1] - The conference call to discuss these results will be hosted by CEO Erez Meltzer and CFO Ran Daniel at 8:30 a.m. ET [1] Company Overview - Nanox is focused on transitioning to preventive healthcare through affordable medical imaging technologies utilizing advanced AI and proprietary digital X-ray sources [3] - The company's vision includes expanding its technology's reach beyond hospitals, providing a comprehensive solution from scan to diagnosis, and leveraging AI for improved diagnostic accuracy [4] Product Ecosystem - Nanox.ARC is a multi-source digital tomosynthesis system designed to be cost-effective and user-friendly [4] - Nanox.AI LTD offers an AI-based suite of algorithms that enhance routine CT imaging readings to detect early signs of chronic diseases [4] - Nanox.CLOUD is a cloud-based platform for managing data from Nanox devices, providing tools for in-depth imaging analysis [4] - Nanox.MARKETPLACE is a decentralized marketplace that offers remote access to radiology and cardiology experts, along with a teleradiology services platform [4]

Core Insights - Nanox Imaging Ltd has entered into a distribution agreement with EXRAY, a leading Czech radiography supplier, to introduce its advanced imaging solutions in the Czech Republic [1][4] - The Nanox.ARC, a multi-source digital tomosynthesis system, is designed to provide enhanced diagnostic capabilities at a lower cost compared to traditional systems and has received CE Mark certification for commercialization in the EU [2][4] - EXRAY holds over 50% market penetration in the Czech Republic, with installations in more than half of the country's 200 healthcare facilities, making it a strategic partner for Nanox [3][4] Company Overview - Nanox focuses on transitioning to preventive healthcare through affordable medical imaging technologies, leveraging advanced AI and proprietary digital X-ray sources [5] - The Nanox ecosystem includes various components such as Nanox.ARC, Nanox.AI LTD, Nanox.CLOUD, and Nanox.MARKETPLACE, aimed at improving early detection and treatment of diseases [6] Strategic Importance - The partnership with EXRAY is seen as a significant milestone in Nanox's European expansion, utilizing EXRAY's established relationships with healthcare providers to enhance access to imaging services [4] - EXRAY's CEO emphasized the potential for improved diagnostic capabilities and patient outcomes through this collaboration [4]

Core Insights - Nanox Imaging Ltd has announced a collaboration with Monarch Medical Management and Billing LLC to deploy advanced imaging solutions across various healthcare segments, including workers' compensation, nursing homes, and outpatient clinics [1][2][4] Group 1: Collaboration Details - The collaboration aims to establish a comprehensive imaging network by deploying Nanox's technology across Monarch's associated healthcare facilities, with over a dozen initial sites identified for a proof-of-concept phase [2] - Nanox's advanced imaging services will be accessible to patients in multiple care settings, including the Nanox.ARC system, AI-powered software for analyzing CT scans, and teleradiology services [3][4] Group 2: Strategic Goals - The collaboration addresses critical imaging access challenges by providing faster access to high-quality imaging services, which can accelerate accurate diagnosis and treatment decisions for patients [4] - Nanox's vision includes expanding its technology reach beyond hospital settings, aiming for a seamless end-to-end solution from scan to diagnosis, leveraging AI for improved efficiency in medical imaging [6] Group 3: Company Background - Nanox is focused on transitioning the world to preventive healthcare through affordable medical imaging technologies based on advanced AI and proprietary digital X-ray sources [5] - The Nanox ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all aimed at enhancing early detection and treatment to improve health outcomes globally [6]

Core Insights - Nanox Imaging Ltd. reported a net loss of $14.7 million for Q2 2025, an increase from a net loss of $13.6 million in Q2 2024, primarily due to higher gross loss and finance expenses [4][15] - The company generated revenue of $3.0 million in Q2 2025, up from $2.7 million in Q2 2024, driven by teleradiology services, imaging systems sales, and AI solutions [5][8] - Nanox is on track to meet its year-end deployment target for the Nanox.ARC system, with a growing commercial pipeline and a breakthrough in the European market [3][18] Financial Performance - The gross loss for Q2 2025 was $3.2 million, with a gross loss margin of 107%, compared to a gross loss of $2.9 million and a margin of 106% in Q2 2024 [6][8] - Non-GAAP gross loss for Q2 2025 was $0.6 million, compared to $0.2 million in Q2 2024, indicating a worsening trend in operational efficiency [16][47] - Research and development expenses remained stable at $4.8 million for both Q2 2025 and Q2 2024, while sales and marketing expenses increased to $1.2 million from $0.8 million [12][13] Business Developments - The company has expanded its customer base, including major medical imaging center chains in the U.S., and is preparing for the first system shipment to Romania [8][3] - Nanox has notified the FDA of its intent to submit the TAP2D software module for a 2D view image output, enhancing the functionality of the Nanox.ARC systems [8] - A multi-year Volume Supply Agreement was established with Fabrinet to support scalable production of Nanox.ARC X [8] Liquidity and Capital Resources - As of June 30, 2025, the company had total cash and equivalents of $62.6 million, down from $83.5 million at the end of 2024, with a negative cash flow from operations of $19.6 million during the reported period [19][20] - The total assets decreased to $184.2 million from $210.0 million at the end of 2024, reflecting a decline in cash and marketable securities [30][20] Shareholder Information - The company had approximately 63.9 million shares outstanding as of June 30, 2025, a slight increase from 63.8 million shares at the end of 2024 [21][20] - The accumulated deficit increased to $401.7 million as of June 30, 2025, compared to $373.7 million at the end of 2024 [30][20]

Core Viewpoint - Nanox Imaging Ltd is set to report its financial results for Q2 2025 on August 12, 2025, with a conference call scheduled for 8:30 a.m. ET to discuss these results and provide a business update [1]. Company Overview - Nanox is focused on advancing preventive healthcare through affordable medical imaging technologies that utilize advanced AI and proprietary digital X-ray sources [3]. - The company's vision includes expanding its technology's reach beyond hospital settings, offering a comprehensive solution from scanning to diagnosis, and leveraging AI for improved diagnostic accuracy [4]. Product and Service Ecosystem - Nanox.ARC: A multi-source digital tomosynthesis system that is cost-effective and user-friendly [4]. - Nanox.AI LTD: A subsidiary that provides AI-based algorithms to enhance routine CT imaging readings, focusing on early signs of chronic diseases [4]. - Nanox.CLOUD: A cloud-based platform for managing data from Nanox devices, offering tools for detailed imaging analysis [4]. - Nanox.MARKETPLACE: A decentralized marketplace through USARAD Holdings Inc. that provides remote access to radiology and cardiology experts, along with a teleradiology services platform [4].

Company Overview - Nanox Imaging Ltd (NASDAQ: NNOX) is an innovative medical imaging technology company focused on transitioning to preventive health care through affordable medical imaging technologies based on advanced AI and proprietary digital X-ray sources [3][4]. Upcoming Event - Nanox will participate in the Sidoti Small Cap Conference, scheduled for June 11-12, 2025, with management presenting on June 11 at 1:45 PM ET [1]. Technology and Solutions - The company aims to expand the reach of its technology beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, enhancing efficiency in routine medical imaging processes [4]. - Nanox's ecosystem includes several components: - Nanox.ARC, a cost-effective multi-source digital tomosynthesis system - Nanox.AI Ltd., which offers AI-based algorithms to augment routine CT imaging readings - Nanox.CLOUD, a cloud-based platform for data management and imaging analysis - Nanox.MARKETPLACE, a decentralized marketplace for remote access to radiology and cardiology experts [4]. Vision and Goals - The company's vision is to improve early detection and treatment of diseases, ultimately enhancing health outcomes worldwide [4].